Lantheus (NASDAQ:LNTH) and Akers Biosciences (NASDAQ:AKER) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.
This table compares Lantheus and Akers Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Lantheus has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Akers Biosciences has a beta of -0.86, meaning that its stock price is 186% less volatile than the S&P 500.
Insider & Institutional Ownership
93.3% of Lantheus shares are held by institutional investors. Comparatively, 50.2% of Akers Biosciences shares are held by institutional investors. 1.2% of Lantheus shares are held by company insiders. Comparatively, 8.9% of Akers Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Lantheus and Akers Biosciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Lantheus||$331.38 million||2.03||$123.38 million||$1.00||17.47|
|Akers Biosciences||$3.93 million||3.24||-$7.36 million||N/A||N/A|
Lantheus has higher revenue and earnings than Akers Biosciences.
This is a breakdown of recent ratings and target prices for Lantheus and Akers Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Lantheus presently has a consensus target price of $20.50, suggesting a potential upside of 17.34%. Given Lantheus’ higher probable upside, equities research analysts clearly believe Lantheus is more favorable than Akers Biosciences.
Lantheus beats Akers Biosciences on 9 of the 11 factors compared between the two stocks.
Lantheus Company Profile
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Akers Biosciences Company Profile
Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ?Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth ?Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.